Influenza remains a major public health challenge, highlighting the need for broadly protective vaccines. Building on mouse studies of chimeric and mosaic hemagglutinin mRNA-LNP vaccines, Pardi and colleagues evaluated these vaccines in non-human primates. Mosaic hemagglutinin vaccination elicited strong, broadly reactive antibodies against different influenza B viruses in monkeys.

The generation of memory B cells following influenza virus vaccination and their rapid recruitment into the virus-specific immune response following infection is an essential component of vaccine-indu...

Dairy cows are protected from H5N1 influenza by an mRNA vaccine.

The Optimal Gold Standard Size of LNPs: Ideal Particle Diameter in Nanometers， Particle size stands as a make-or-break critical parameter in the in vivo delivery journey of mRNA-LNP therapeutics. U

What Is The Drug Loading Capacity of LNP?， In the development and quality control of mRNA-LNP formulations, entrapment efficiency (EE) ranks among the most frequ

We generated an mRNA vaccine that expresses the hemagglutinin (HA) of A/dairy cattle/Texas/24-008749-002/2024, which is representative of HPAI clade 2.3.4.4b H5N1 viruses currently circulating in dairy cattle in the USA4. We vaccinated four lactating dairy cows intramuscularly with 500 μg of H5 mRNA–LNP in saline and then boosted intramuscularly with the same vaccine dose 3 weeks later (Fig. 1a). As a control, we intramuscularly injected four additional lactating cows twice with saline (Fig. 1a). Animals in our study were obtained from an HPAI-monitored Holstein dairy herd in Pennsylvania and ranged from 2 to 8 years of age (Supplementary Table 1). We collected serum samples at 0, 7, 21, 28, 41 and 49 days after the initial vaccination and collected milk samples daily. Both unvaccinated and vaccinated animals were challenged with infectious clade 2.3.4.4b H5N1 virus through intramammary inoculation 49 days after the first vaccination. The vaccine was well tolerated, with no obvious adverse effects. Previous studies found trace amounts of vaccine-related mRNA in human milk in some individuals shortly after SARS-CoV-2 mRNA–LNP vaccination18,19,20. Therefore, we completed experiments to determine whether we could detect H5 mRNA–LNP in bovine milk samples obtained after vaccination. First, we established a sensitive quantitative PCR assay...

We generated an mRNA vaccine that expresses the hemagglutinin (HA) of A/dairy cattle/Texas/24-008749-002/2024, which is representative of HPAI clade 2.3.4.4b H5N1 viruses currently circulating in dairy cattle in the USA4. We vaccinated four lactating dairy cows intramuscularly with 500 μg of H5 mRNA–LNP in saline and then boosted intramuscularly with the same vaccine dose 3 weeks later (Fig. 1a). As a control, we intramuscularly injected four additional lactating cows twice with saline (Fig. 1a). Animals in our study were obtained from an HPAI-monitored Holstein dairy herd in Pennsylvania and ranged from 2 to 8 years of age (Supplementary Table 1). We collected serum samples at 0, 7, 21, 28, 41 and 49 days after the initial vaccination and collected milk samples daily. Both unvaccinated and vaccinated animals were challenged with infectious clade 2.3.4.4b H5N1 virus through intramammary inoculation 49 days after the first vaccination. The vaccine was well tolerated, with no obvious adverse effects. Previous studies found trace amounts of vaccine-related mRNA in human milk in some individuals shortly after SARS-CoV-2 mRNA–LNP vaccination18,19,20. Therefore, we completed experiments to determine whether we could detect H5 mRNA–LNP in bovine milk samples obtained after vaccination. First, we established a sensitive quantitative PCR assay...

Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1 virus has recently emerged in dairy cattle in the USA, leading to mastitis and sharp reductions in milk production. The main site of H5N1 viral replication is the mammary tissue rather than the respiratory tract and viral transmission between animals is thought to occur through viral shedding in milk. Here, we generate an mRNA-lipid nanoparticle (mRNA-LNP) vaccine encoding the hemagglutinin (HA) of A/dairy...

What Is the Encapsulation Efficiency of LNPs and Why Is It Critical?， Within the quality control framework of mRNA-LNP therapeutics, one metric weighs heavier on production costs than part

mRNA-LNPs vaccine provides full protection against a lethal bacterium.

  Postdoc position in mRNA-LNP structural characterization   Position: A postdoctoral research position is available in the Nanoassembly Lab at the University of Texas at Austin, focused on structural characterization of mRNA-lipid nanoparticles (LNPs) using small-angle X-ray scattering (SAXS)

Potency testing is essential for drug product release and stability but is challenging for mRNA lipid nanoparticle (LNP) vaccines because antibody-based assays require highly specific and functional antibodies that are costly and labor-intensive to manufacture. In Molecular Therapy Advances, Fox et al. introduce pSIM—pulsed stable isotope labeling by amino acids in cell culture (SILAC) internal dosing control (IDC) mass spectrometry (MS)—an antibody-free in vitro potency assay. By co-processing test and reference LNPs, pSIM supported EC50-based or dosing-control-normalized linear slope readouts.

Join us for an insightful webinar covering advancements in mRNA and lipid nanoparticle technology for in vivo CAR-T therapy, focusing on durability and precision.